ArticleJournal of biopharmaceutical statistics2023
Diagnostic evaluation of pharmacokinetic features of functional markers.
Article in Journal of biopharmaceutical statistics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
The dynamicity of functional (curve) markers from modern clinical studies offers deeper insights into complex disease physiology. A frequent clinical practice is to examine various 'pharmacokinetic features' of functional markers (definite integral, maximum value, time to maximum, etc.) that reflect important physiological underpinnings. For instance, the current diagnostic procedure for kidney obstruction is to examine several pharmacokinetic features of renogram curves characterizing renal function. Motivated by such clinical practices, we develop a statistical framework for evaluating diagnostic accuracy of pharmacokinetic features using area under the receiver operating characteristic curve (AUC). The major challenge is that functional markers are observed at discrete time points with measurement error. To address this challenge, we develop a two-stage non-parametric AUC estimator based on summary functionals providing unified representation of various pharmacokinetic features and study its asymptotic properties. We also propose a sensible adaptation of a semiparametric regression model that can describe heterogeneity of AUC across different subpopulations, while appropriately handling discreteness and noise in observed functional markers. Here, a novel data-driven approach that balances between bias and efficiency of the regression coefficient estimates is introduced. Finally, the framework is applied to rigorously evaluate pharmacokinetic features of renogram curves potentially useful for detecting kidney obstruction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.